Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman
Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c
EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)
S-3/A - Autonomix Medical, Inc. (0001617867) (Filer)
S-3 - Autonomix Medical, Inc. (0001617867) (Filer)
8-K - Autonomix Medical, Inc. (0001617867) (Filer)
8-K - Autonomix Medical, Inc. (0001617867) (Filer)
10-Q - Autonomix Medical, Inc. (0001617867) (Filer)
8-K - Autonomix Medical, Inc. (0001617867) (Filer)
8-K - Autonomix Medical, Inc. (0001617867) (Filer)
424B4 - Autonomix Medical, Inc. (0001617867) (Filer)
EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
3 - Autonomix Medical, Inc. (0001617867) (Issuer)
4 - Autonomix Medical, Inc. (0001617867) (Issuer)
New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that European Patent Office (EPO) has granted Patent No. 3,226,792 (the ‘792) titled, "Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and
Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has engaged U.S. and international-based medical experts in interventional radiology and cancer pain to guide the Company's U.S. clinical and regulatory path to ensure pre-clinical and clinical studies meet the needs of the Company's expected FDA De Novo submission in 2026. The Company's
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Netherlands. Details of the poster presentation are as follows: Title: Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study Authors: Robert S. Schwartz, MD, Chief Medical Officer
THE WOODLANDS, TX, March 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix's Board of Directors approved the grant of an inducement stock option on March 17, 2025 to purchase 7,500 shares of the Company's common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual's employment compensation and was granted as an inducement material to their star
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the United States Patent and Trademark Office (USPTO) has issued
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency ("RF") Generator On track for Investigational Device Exemption ("IDE") submission and, if approved, U.S. clinical trial initiation in 2025 for pancreatic cancer pain Milestone advances proprietary sensing and ablation catheter technology into a fully integrated transvascular treatment platform THE WOODLANDS, TX, March 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced it has completed the integration and d
THE WOODLANDS, TX, March 06, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced its abstract has been accepted for poster presentation at the 2025 Society of Interventional Radiology ("SIR") Annual Scientific Meeting being held March 29-April 2, 2025 in in Nashville, Tennessee. Details of the accepted abstract are as follows: Title: Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based AblationPresenter: Bela Kis, MD
THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the LSI USA '25 Emerging Medtech Summit on Tuesday, March 18, 2025 at 7:35 AM PT. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. The in-person presentation will be accessibl
Presentation to highlight Autonomix's catheter-based technology and key findings from lead-in patients in ongoing human clinical trial in pancreatic cancer pain patients THE WOODLANDS, TX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will present its technology and lead-in subject findings in a podium presentation at the 2025 Cardiovascular Research Technologies (CRT) Annual Meeting being held March 8-11, 2025 in Washington, DC.The podium presentation will be part of the Innovation HUB session which features companies with innovat
On-demand video webcast now available here THE WOODLANDS, TX, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Autonomix in 2025. The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Compa
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)
SC 13D - Autonomix Medical, Inc. (0001617867) (Subject)